miR-638 acts as an oncogene and predicts poor prognosis in renal cell carcinoma.

Pan, Xiang; He, Tao; Peng, Xiqi; Li, Hang; Zhang, Fangting; Lai, Yongqing

Pan, Xiang; He, Tao; Peng, Xiqi; Li, Hang; Zhang, Fangting; Lai, Yongqing.

Afiliación

Pan X; Department of Urology, Affiliated Hospital of Yangzhou University, Yangzhou University Yangzhou 225000, Jiangsu, P. R. China.
He T; Department of Urology, Shenzhen People's Hospital (The Second Clinical Medical College, Jinan University; The First Affiliated Hospital, Southern University of Science and Technology) Shenzhen 518020, Guangdong, P. R. China.
Peng X; Guangdong and Shenzhen Key Laboratory of Male Reproductive Medicine and Genetics, Peking University Shenzhen Hospital Shenzhen 518036, Guangdong, P. R. China.
Li H; Shantou University Medical College Shantou 515041, Guangdong, P. R. China.
Zhang F; Guangdong and Shenzhen Key Laboratory of Male Reproductive Medicine and Genetics, Peking University Shenzhen Hospital Shenzhen 518036, Guangdong, P. R. China.
Lai Y; Guangdong and Shenzhen Key Laboratory of Male Reproductive Medicine and Genetics, Peking University Shenzhen Hospital Shenzhen 518036, Guangdong, P. R. China.

Am J Transl Res ; 12(7): 3645-3659, 2020.

Article en En | MEDLINE | ID: mdl-32774724

Palabras clave

biomarkers; miR-638; microRNA; oncogene; renal cell carcinoma

Texto completo

Añadir a Mi BVS

Imprimir

XML

PubMed Links

Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Tipo de estudio: Prognostic_studies / Risk_factors_studies Idioma: En Revista: Am J Transl Res Año: 2020 Tipo del documento: Article Pais de publicación: Estados Unidos

Texto completo

Añadir a Mi BVS

Imprimir

XML

PubMed Links

Buscar en Google